

PROJECT SUMMARY SHEET

TITLE: MATCH – Mesothelioma And Translational Clinical and Health-related data – a biological and clinical observational study

RESEARCH ENTITY: Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo di Alessandria (*SS Antonio and Biagio and Cesare Arrigo Hospital*) in collaboration with the Istitituto di Ricerche Farmacologiche Mario Negri IRCCS (*Mario Negri IRCCS Pharmacology Research Institute*)

PROJECT LOCATION: Multicenter study:

AO Alessandria

Ospedale Santo Spirito Casale Monferrato

Ospedale San Gerardo Monza

Istituto Clinico Humanitas di Rozzano

Istituto Clinico Humanitas Gavazzeni

IOV Padova

Genova Ospedale Villa Scassi

MAIN CONTACT:

- First and last name: Federica Grosso
- Email: federica.grosso@ospedale.al.it Telephone: 0131206155
- Work location: Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo di Alessandria

PROJECT PARTICIPANTS:

- First and last name: Maurizio D’Incalci
- Email: maurizio.dinclaci@marionegri.it Telephone: 0239014571
- Work location: Istituto di Ricerche Farmacologiche Mario Negri IRCCS

- First and last name: Fiorella Calabrese
- Email: fiorella.calabrese@unipd.it Telephone: 049637142
- Work location: Dipartimento di Scienze Cardio-Toraco-Vascolari e Sanità Pubblica dell’Università di Padova

ABSTRACT/SUMMARY

INTRODUCTION: The purpose of the project is to increase our knowledge about the biological, genetic and molecular aspects of malignant pleural mesothelioma (MPM), a generally rare tumor with a poor prognosis and very few available treatments, which are given based on the clinical stage and characteristics of the patient rather than the characteristics of the disease. We have planned to conduct an integrated analysis of the genomic, transcriptomic and epigenetic aspects of the tumor and its microenvironment, together with the characteristics of the tumor and its histology in particular, response to treatment and patient survival. The ultimate goal of the project is to develop effective tools for the diagnosis, prognostic stratification and implementation of more “personalized” therapeutic approaches. The study is currently ongoing.

- **METHOD:** The study is designed as an observational, multicenter trial with a retrospective cohort of 130 patients divided according to histology to identify the biological factors (through transcriptomic analysis, together with histological and immunological parameters), which will be subsequently validated in a prospective cohort of 50 newly diagnosed patients. Tissue samples for all patients must be available upon diagnosis.
- **OBJECTIVES:** The objectives of the project include integrating the RNAseq with the histological and immunological parameters resulting from the centralized pathology review to assess the characteristics of the tumor cells and the inflammatory infiltrate.